Comparisons with the placebo patients from the PROACT II trial
| PROACT II placebo (n=59) | Penumbra MCA group (n=89) | p Values* | |
| Age (years) (mean) | 64 | 66 | 0.4097 |
| Female (%) | 39 | 51 | 0.1814 |
| Baseline NIHSS (median (range)) | 17 (4–28) | 15 (5–25) | NA |
| TIMI 2–3 | 18% | 88% | <0.0001 |
| Symptomatic ICH | 2% | 6% | 0.4026 |
| mRS< at 90 days | 25% | 51% | 0.0037 |
| Death at 90 days | 27% | 15% | 0.0895 |
↵* p value is for testing against PROACT II placebo using a two tailed Fisher's exact test.
ICH, intracerebral hemorrhage; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.